Insmed (INSM) Stock Forecast & Price Target

Insmed is attractive fundamentally because it combines an already commercial respiratory franchise with a deep, differentiated pipeline spanning respiratory, immunology and inflammation, and rare disease, while the company’s two approved products and late-stage programs offer multiple shots on goal across large unmet-need markets. The near-term thesis is strengthened by strong 2Q 2026 execution, with Brinsupri sales beating expectations and Arikayce revenue of $116.3M also modestly ahead of estimates, while management’s updated guidance and the model’s Brinsupri revenue increases of about 8% in 2026 and 15% in 2027 support faster growth from a base that already includes roughly $1.2B of cash and cash equivalents. Longer term, the company has visible catalysts from Brinsupri pricing and Japan decisions in 2H26, potential U.S. and Japan frontline Arikayce launches in 2027, and TPIP readouts beginning in December 2028, and even after factoring in cash taxes in FY27E and the paydown of liabilities, the outlook is underpinned by commercial leverage, expanding ex-U.S. contribution, and a research engine with multiple modalities that can create additional value.

Insmed is facing a weaker fundamental setup because the rebuilt model cuts FY27E/FY28E revenue by 10%, removes modeled EU Brinsupri contributions due to a paused launch amid pricing-policy and budget constraints, and assumes a slower frontline Arikayce ramp that depends on physician education rather than a simple sales-force expansion. The company’s near-term earnings power also deteriorates materially as FY27E EPS falls to $1.24 from $3.26, driven by a roughly $531 million decline in operating income split between about 60% lower revenue and 40% higher opex, while 2027 R&D rises to $1,022 million and SG&A to $1,133 million as four TPIP Phase 3 programs move forward concurrently. Even with large long-term peak revenue opportunities for Brinsupri and TPIP, the outlook remains cautious because the business must absorb higher product costs from Brinsupri royalties, an outsourced manufacturing model, and a 2027 investment year that compresses margins and delays the earnings inflection until much later launch timing.